Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyoscine butylbromide versus placebo as an adjunct to misoprostol for cervical ripening in nulliparous women
PACTR202603552803085Phase 3Not yet recruiting
- Sponsor
- Oyelami Olusegun Samuel
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in None comparing Hyoscine butylbromide + misoprostol with Placebo + misoprostol (2 arms). Primary endpoint: Time to achieve cervical ripening. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
hyoscine butylbromidemisoprostol
Beyond the preview
Go deeper on PACTR202603552803085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202603552803085.